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Abstract	  
Microfluidics gained prominence with the application of microelectromechanical systems 
(MEMS) to chemistry and biology in an attempt to benefit from the miniaturization of 
devices for handling of minute fluid samples under precisely controlled conditions. The 
field of microfluidics exploits the differences between micro- and macro-scale flows, for 
example, the absence of turbulence, electro-osmotic flow, surface and interfacial effects, 
capillary forces in order to develop scaled-down biochemical analytical processes.1,2  The 
field also takes advantage of MEMS and silicon micromachining by integrating micro-
sensors, micro-valves, and micro-pumps as well as physical, electrical, and optical 
detection schemes into microfluidics to develop the so-called “micro-total analysis systems 
(µTAS)” or “lab-on-a-chip” devices.3,4  The use of silicon in the early years of 
miniaturization during 1980s was self-limiting to the growth of the field of microfluidics 
primarily due to its high cost and inaccessibility of manufacturing, and to some extent due 
to its incompatibility with light microscopy. After mid 1990s there has been a major leap in 
progress with the application of soft lithography using polydimethylsiloxane to engineer 
complex microfluidics devices as well as the ability to manufacture plastics at a micron 
scale resolution.5,6 
	   	   	  
 
In 2006, Dr. Whitesides described the field as: “It [microfluidics] is the science and 
technology of systems that process or manipulate small (10-9 to 10-18 litres) amounts of 
fluids, using channels with dimensions of tens of hundreds of micrometers”.1 On the other 
hand, the ability to process ‘real world-sized’ volumes (10-4 to 10-1 litres) that would enable 
a wide range of industrial and medical applications has been a major challenge since the 
beginning of the field of microfluidics.7 This begs the question whether it is possible to 
take advantage of microfluidic precision without the limitation on throughput required for 
large-volume processing? The challenge is compounded by the fact that physiological 
fluids are non-Newtonian, heterogeneous, and contain viscoelastic living cells that 
continuously responds to the smallest changes in their microenvironment. Starting in 
2000s, we have initiated efforts to explore the use of microfluidics to process and 
manipulate volumes of physiological fluids that are five to ten orders of magnitude more 
than the amounts typically used in microfluidics.8-12   Our efforts to advance the field of 
microfluidics to process large-volumes of fluids were counterintuitive and not anticipated 
by the conventional wisdom at the inception of the field. We showed that the new large-
volume cell separation methods can be more than just a scale-up approach via 
parallelization of existing µTAS methods.  We metaphorically called this “hooking garden 
hose to microfluidic chips.” 
 
In an early attempt, we developed a microfluidic chip to process milliliters volumes of 
whole blood (~5x10-3 liters) without any dilution to isolate extremely rare (1 in 1-10 billion 
blood cells) circulating tumor cells.12 We used enabling aspects of physics of microfluidics 
to eliminate multiple steps used in bulk techniques to provide very uniform and gentle flow 
conditions to capture rare tumor cells in whole blood. We created a microfluidic platform 
that contains about 80,000 microposts that are distributed in such a manner to maximize the 
frequency of contact between cells and chemically modified microposts with an antibody to 
selectively bind tumor cells. The chip interrogates about 2x10+6 cells·s-1 or each micropost 
20-30 cells·s-1, which clearly brings the power of multiplexing and precise flow control 
inherent to microfluidics. Moreover, the maximum shear stress by a cell near the micropost 
surface was estimated to be 0.4 dyn·cm-2, which is significantly lower than typical 
physiological shear stress experienced by cells, enabling sorting of live cells. Overall, this 
study has become a major driving force for the field and paved the way for subsequent 
studies exploring the use of microfluidics to manipulate complex bodily fluids.   
 
Subsequently, we and others have also developed alternative approaches to use 
microfluidics for the isolation of rare cells from whole blood.  We used micro-vortex 
generating device to ensure effective contacts of cells with antibody-coated surfaces to bind 
target cells using a simple geometry that is amenable for large-scale manufacturing.13  We 
integrated ultra-porous forests of vertically aligned carbon nanotubes combining 
microporosity and nanoporosity to achieve simultaneous mechanical filtration and chemical 
bioparticle capture that enables simultaneous isolation of three different particle types 
ranging three orders of magnitude in size.14  The use of ultra nanoporous posts improved 
particle interception compared to solid posts via the increase of direct interception and the 
reduction of near-surface hydrodynamic resistance. We also developed a microchip 
incorporating porous, fluid-permeable surfaces functionalized with cell-specific antibodies 
to capture a rare subpopulation of target cells with excellent selectivity and significantly 
enhanced throughput.15 The efficiency of this microfluidic platform arises both from 
enhanced mass transport to porous surface and from enhanced cell-surface interactions that 
	   	   	  
promote dynamic cell rolling adhesion with high specificity. These and other so-called 
‘positive’ sorting microfluidic devices demonstrated the power of microfluidics for rare cell 
sorting from large-volumes of complex fluids.  
 
More recently, we integrated multi-physics processing on a single microfluidic device to 
sort rare tumor cells from blood by “negative depletion,” that is by removing tens of 
billions of blood cells without losing a few rare tumor cells.16,17,18 Advantages of this 
approach for cancer detection are considerable in that the microfluidic device makes no a 
priori assumption about tumor cells and as such it applies to all cancers and all tumor cells 
in whole blood irrespective of size, phenotype, or other properties.  After magnetic labeling 
of white blood cells using microbeads coated with antibodies, this microfluidic cell 
separation platform integrates three sequential microfluidic technologies to impart exquisite 
control over billions of particles, namely, (i) removal of smaller red blood cells and 
platelets from larger white blood cells and tumor cells using deterministic lateral 
displacement, (ii) the alignment of nucleated cells within a microfluidic channel using 
inertial focusing principles, and (iii) the deflection of magnetically tagged white blood cells 
into a waste channel while tumor cells sorted into a product channel. The chip processes 
10-20 mL·h-1 through ~1.5 million microscopic features, 256 individual deterministic 
lateral displacement arrays, and 4 parallel inertial focusing channels.  More importantly, we 
use the power of microfluidic multiplexing to shorten the transit time in the chip to only 
less than a second so the cells are isolated unaltered for subsequent molecular analysis. The 
integration of multi-physics sorting of only a few rare cells at extremely high-throughput 
from blood containing over 50 billions of cells provides an excellent example of the 
enabling aspect of microfluidics physics and technology.  
 
We also pioneered using inertial forces in microchannel flows for controlling cell and 
particle motion, which enabled extremely high-throughput manipulation and sorting of 
bioparticles.19As much as the framework in the field was that microfluidic systems operate 
at low Reynolds number in the absence of inertial forces, we showed that inertia is not only 
critical to low Reynolds number flows in microchannels but it can also be easily exploited 
to achieve exquisite control over manipulation of bioparticles and cells. We investigated 
the particle migration transverse to fluid streamlines in highly confined microchannel 
systems where the particle (cell) size approaches the channel dimensions.  We used inertial 
forces in microfluidic systems in laminar flow at particle Reynolds number of Rep~O(1) to 
focus randomly distributed particles and cells continuously and at high rates to a single 
streamline. This effect was first reported experimentally for particles flowing through 
macroscale large pipes, the so-called “tubular pinch effect.”  However, no particle 
manipulation was accomplished at the macroscale flow mainly due to the difficulty in 
isolating particles from a large focused annulus in a tube flow. On the other hand, 
microscale effects in microchannel flows can be used to move particles across streamlines 
to predictable equilibrium positions within a flow and to differentially order particles of 
different sizes, continuously, at high throughputs, with no external forces, and also sort 
these particles by size and other physicochemical attributes.20-23 We also used particle 
tracking analysis to probe the effect of inertial focusing of cells in whole blood (non-
Newtonian) or diluted (Newtonian) blood.24  We observed the inertial focusing behavior of 
white blood cells and tumor cells in whole blood despite steric interference from 
overwhelming number of red blood cells. Since the initial publication, we and others have 
explored inertial microfluidics to precisely manipulate and sort bioparticles.25-26   
 
	   	   	  
We also advanced the use of inertial microfluidics to several other untapped processes. We 
developed a microfluidic device that couples the phenomenon of inertial focusing and 
highly controllable hydraulic resistance micro-siphoning channels to achieve controlled 
bioparticle concentration.27 Concentrating cells and bioparticles using centrifugation is a 
ubiquitous preparatory step in many biomedical applications and assays, and it also 
emerged as an immediate need in microfluidics, as devices that are capable of processing 
larger volumes of blood were producing dilute solutions of targeted cells. However, 
centrifugation suffers from long exposure of bioparticles to heightened centrifugal forces, 
formation of compacted pellet, and it is inherently variable and low yield process, 
especially when applied to larger volumes of samples.  By taking the concept of repetitive 
fluid removal and refocusing to an extreme, a parallelized and serially integrated version of 
our microfluidic concentrator chip is able to reach a volume reduction factor >400 of a 
cellular suspension in a continuous manner.  The microchip operates under continuous flow 
conditions, exposes cells passing through the device to uniform conditions, and has a transit 
time of only ~100 ms.  More recently, we also developed a ‘non-equilibrium’ inertial 
separation method for ultra-high throughput and large-volume blood fractionation.28 We 
devised a fully-parallelized microchip (104 devices) that can fractionate 400 mL of whole 
blood (containing ~2 trillion cells) within 3 hours to debulk red blood cells and platelets to 
produce white blood cell fractionate. The processing rate is >200 million cells·s-1 resulting 
in fractionation of blood and bone marrow without clogging.28 This was achieved because 
non-equilibrium inertial focusing in repeated units enables sorting cells by size without 
contacting surfaces.  Despite the ultra-high throughput processing, the cells are alive and 
unaltered as the residence time on the chip is less than a second. More recently, we put 
forth the use of oscillatory flows in microchannels under inertial focusing conditions to 
effectively create an ‘infinitely’ long microchannel.  This enabled us to focus particles that 
are sub-micron size in microchannels at very low pressure drops; hence enabling entirely 
new opportunities in a previously unexplored particle Reynolds number range (i.e. 
Rep~O(10-2)). 
 
In our quest to push the limits of inertial microfluidics, we also demonstrated inertia-elastic 
focusing of particles and cells in a previously entirely unexplored regime of channel 
Reynolds numbers of up to Re≈10,000 that was accessed through the use of a rigid 
microfluidic device.29  We showed that on addition of micromolar concentrations of 
biopolymeric drug reducing agents, the resulting fluid viscoelasticity can be used to control 
the focal position of particles at Reynolds numbers up to Re≈10,000 in a single 
microchannel with corresponding flow rates and particle velocities up to 50 mL·min-1 (or 3 
L·h-1) and 130 m·s-1 (or 468 km·h-1), respectively.  We demonstrated that the focusing 
performance of the microfluidic device actually improves with increasing flow throughput 
up to Re~O(103) and can be achieved when both elasticity and inertia are present (i.e., 
Wi>>1 and Re>>1).  We found that viscoelastic normal stresses drive the deterministic 
particle migration in this regime.  We also note that our results represent an important 
improvement of three to four orders of magnitude in flow rate within only a single 
microchannel over previous studies of particle migration. 
 
Finally, our recent efforts to use microfluidics have focused on collecting multicellular 
‘clusters’ of tumor cells from whole blood.30 Existing technologies for cell sorting are 
designed to isolate single tumor cells despite the fact that there is growing evidence that 
clusters of tumor cells are highly metastatic.  We developed a microchip technology to 
capture tumor cell clusters from unprocessed blood. The cluster chip uses specialized 
	   	   	  
bifurcating micro-traps under extremely low shear stress conditions at peak flow speed of 
~70 µm·s-1, so that the clusters isolated independent of their deformability and the delicate 
cell-cell junctions are not damaged.  The overall chip is multiplexed with 33,000 
microscopic triangular structures forming 4,096 parallel trapping paths such that it can 
interrogate blood sample at an impressive overall volumetric flow rate of 2.5 mL·h-1 
(~4x10-5 lt·s-1). We have advanced the cluster sorting to a continuous flow sorting approach 
using deterministic lateral displacement approach based on size and asymmetry. 31 Efficient 
sorting of living tumor clusters enables for the first time the detailed characterization of 
their role in metastasis. 32 
 
In summary, the use of microfluidics to process large-volumes of complex fluids has found 
broad interest in both academia and industry at an unprecedented rate due to its broad range 
of utility in medical and industrial applications. Microfluidics for the macro-world and 
related enabling technologies and fundamental physicochemical principles are likely to 
remain a highly active field for years to come. 
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